Article
Oncology
Shinichi Tate, Kyoko Nishikimi, Ayumu Matsuoka, Satoyo Otsuka, Yuki Shiko, Yoshihito Ozawa, Yohei Kawasaki, Makio Shozu
Summary: The study found that incorporating bevacizumab into first-line chemotherapy may improve progression-free survival in patients with advanced clear cell carcinoma.
Article
Oncology
Zhichao Liao, Chao Zhang, Tielong Yang, Haotian Liu, Songwei Yang, Ting Li, Ruwei Xing, Sheng Teng, Yun Yang, Jun Zhao, Gang Zhao, Xu Bai, Lei Zhu, Jilong Yang
Summary: This study confirms the efficacy and safety of chemotherapy combined with Endostar in stage IV soft tissue sarcoma, and identifies undifferentiated polymorphic sarcoma (UPS) as a potential subtype that benefits from this combined treatment.
FRONTIERS IN ONCOLOGY
(2022)
Article
Medicine, General & Internal
Junyue Tao, Hao Yang, Zongyao Hao, Chaozhao Liang, Yingying Du, Chao Zhang, Yu Yin, Jun Zhou
Summary: This case report describes the use of anlotinib combined with chemotherapy in treating recurrent clear cell sarcoma, which has shown promising results and may be an effective treatment option.
Article
Oncology
Jiayi Li, Dongyan Cao
Summary: We developed two prognostic nomograms for predicting recurrence and long-term survival in patients with ovarian clear cell carcinoma (OCCC) after primary treatment, and validated them in patients from the same center. This tool, which uses variables specifically related to OCCC, was more accurate than the FIGO system, making it relatively easy to use in clinic for patient counseling, postoperative management, and follow-up for individual patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Nicholas D. Klemen, Sinchun Hwang, Martina Bradic, Evan Rosenbaum, Mark A. Dickson, Mrinal M. Gounder, Ciara M. Kelly, Mary L. Keohan, Sujana Movva, Katherine A. Thornton, Ping Chi, Benjamin A. Nacev, Jason E. Chan, Edmund K. Bartlett, Allison L. Richards, Samuel Singer, Mark T. A. Donoghue, William D. Tap, Sandra P. D'Angelo
Summary: This study analyzed the response to PD-1 blockade in advanced sarcoma patients, finding that it can result in durable responses but may also lead to hyperprogressive disease (HPD). The clinical and biological characteristics of HPD in sarcoma patients were similar to those with progressive disease (PD), highlighting the need for further research into HPD as a distinct phenomenon.
CLINICAL CANCER RESEARCH
(2022)
Article
Pediatrics
Hui Gao, Qi-Yuan Cheng, Qian Zhao, Long-Xiang Tao, Cheng Zhang
Summary: The incidence of CCSK remains stable over the years with an age-adjusted rate of 0.205 per million in children, with boys and age under 4 being risk factors. The 5-year overall survival rate for CCSK is 87%, but when compared to WT and well-balanced, CCSK shows a significantly poorer outcome.
FRONTIERS IN PEDIATRICS
(2021)
Article
Oncology
Wachiranun Sirikul, Nida Buawangpong, Dumnoensun Pruksakorn, Chaiyut Charoentum, Pimpisa Teeyakasem, Nut Koonrungsesomboon
Summary: This study assessed survival outcomes, prognostic factors, and adverse events in patients with osteosarcoma and Ewing's sarcoma who received chemotherapy. The study found that the 5-year survival probabilities were higher in patients with resectable disease compared to those with unresectable/metastatic disease. Prognostic factors for osteosarcoma included response to neoadjuvant chemotherapy and female gender, while older age was associated with poorer survival outcomes in Ewing's sarcoma. Common adverse symptoms and grade III adverse events during chemotherapy were reported, but there were no chemotherapy-related deaths or anaphylaxis events.
Article
Oncology
Daniel J. Serie, Amanda A. Myers, Daniela A. Haehn, Alexander S. Parker, Essa M. Bajalia, Giovanni A. Gonzalez, Qiongyu Li, Maurice Yu Wong, Kaitlynn C. Moser, Bo Zhou, David D. Thiel
Summary: By using high-throughput glycoproteomics, we identified differential expression of certain glycopeptides associated with progression-free survival in patients with clear cell renal cell carcinoma (ccRCC). These findings suggest that glycoprotein-isoforms may serve as novel biomarkers for clinical diagnosis and prognosis of ccRCC.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2022)
Article
Pharmacology & Pharmacy
Jun Wang, Weichao Tu, Jianxin Qiu, Dawei Wang
Summary: Immune checkpoint inhibitors are a novel therapeutic strategy for various tumors, but their effectiveness and side effects in clear cell renal cell carcinoma (ccRCC) patients vary. Common biomarkers cannot accurately predict ccRCC's response to immunotherapy, necessitating further research and development of predictive models. Model incorporating mutation data, endogenous retrovirus data, and gene copy number data showed good performance in predicting survival and response to immunotherapy in ccRCC patients.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Oncology
A. Smrke, A. M. Frezza, C. Giani, N. Somaiah, M. Brahmi, A. M. Czarnecka, P. Rutkowski, W. Van der Graaf, G. G. Baldi, E. Connolly, F. Duffaud, P. H. Huang, H. Gelderblom, V Bhadri, P. Grimison, A. Mahar, S. Stacchiotti, R. L. Jones
Summary: Clear cell sarcoma (CCS) is a rare and aggressive malignancy with a poor response to systemic therapy for advanced patients, highlighting the need for international, multicenter prospective translational studies to identify new treatment options. Early clinical trial enrollment remains crucial for patients with CCS.
Article
Oncology
A. Smrke, A. M. Frezza, C. Giani, N. Somaiah, M. Brahmi, A. M. Czarnecka, P. Rutkowski, W. Van der Graaf, G. G. Baldi, E. Connolly, F. Duffaud, P. H. Huang, H. Gelderblom, V Bhadri, P. Grimison, A. Mahar, S. Stacchiotti, R. L. Jones
Summary: This retrospective study examined the outcomes of patients with advanced clear cell sarcoma (CCS) who received systemic therapy. The results showed that systemic therapies for soft tissue sarcomas had limited benefits and poor response rates in advanced CCS. International, multicentre translational studies are needed to identify new treatments for this rare subtype.
Article
Pharmacology & Pharmacy
Marie-Sophie Minot-This, Pascaline Boudou-Rouquette, Anne Jouinot, Sixtine de Percin, David Balakirouchenane, Nihel Khoudour, Camille Tlemsani, Jonathan Chauvin, Audrey Thomas-Schoemann, Francois Goldwasser, Benoit Blanchet, Jerome Alexandre
Summary: This study aimed to define the specific threshold of Pazopanib (PAZ) trough concentration associated with better progression-free survival in soft tissue sarcoma patients. The results showed that PAZ C-min < 27 mg/L was independently associated with a risk of progression at 3 months, and a higher average of PAZ C-min was associated with a higher risk of grade 3-4 toxicities.
Article
Urology & Nephrology
Kelly N. Fitzgerald, Cihan Duzgol, Andrea Knezevic, Natalie Shapnik, Ritesh Kotecha, David H. Aggen, Maria I. Carlo, Neil J. Shah, Martin H. Voss, Darren R. Feldman, Robert J. Motzer, Chung -Han Lee
Summary: There is no significant difference in outcomes between immunotherapy-based combinations and tyrosine kinase inhibitor/immune checkpoint inhibitor combination in the treatment of metastatic clear cell renal cell carcinoma (ccRCC), suggesting that the current treatment strategy should not be changed.
Article
Cell Biology
Zhiliang Chen, Zaosong Zheng, Yingwei Xie, Qiyu Zhong, Wentai Shangguan, Yishan Zhang, Dingjun Zhu, Wenlian Xie
Summary: circPPP6R3 is a highly expressed circular RNA in clear cell renal cell carcinoma (ccRCC), and it is associated with the severity and progression of the disease. It interacts with miR-1238-3p and upregulates the expression of CD44, promoting cancer cell proliferation and metastasis. This study provides new insights into biomarkers and potential therapeutic approaches for ccRCC.
CELL DEATH & DISEASE
(2022)
Article
Oncology
B. J. Solomon, H. H. Loong, Y. Summers, Z. M. Thomas, P. French, B. K. Lin, A. Sashegyi, J. Wolf, J. C-H Yang, A. Drilon
Summary: This study identified a strong correlation between the treatment effects on ORR and PFS in randomized clinical trials targeting oncogene-addicted tumors, while a weaker correlation was observed between ORR and OS.
Article
Oncology
Steven Attia, Vanessa Bolejack, Kristen N. Ganjoo, Suzanne George, Mark Agulnik, Daniel Rushing, Elizabeth T. Loggers, Michael B. Livingston, Jennifer Wright, Sant P. Chawla, Scott H. Okuno, Denise K. Reinke, Richard F. Riedel, Lara E. Davis, Christopher W. Ryan, Robert G. Maki
Summary: This study reported the preliminary efficacy and toxicity of regorafenib in Ewing family sarcomas. The results showed that regorafenib had modest inhibitory activity against Ewing family sarcomas, with toxicity consistent with that observed in other studies.
Article
Biochemistry & Molecular Biology
Yuen Bun Tam, Robin L. Jones, Paul H. Huang
Summary: This review provides an overview of molecular profiling studies in Desmoplastic small round cell tumour (DSRCT), highlighting the contributions of genomics, epigenetics, and proteomics in enhancing our understanding of this rare tumor. It also discusses the potential of future integrated studies, including proteogenomics, in further enriching our knowledge and improving outcomes for patients with DSRCT.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
(2023)
Editorial Material
Oncology
Robert G. Maki
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Srivandana Akshintala, Nicole C. Mallory, Yao Lu, Karla Ballman, Scott M. Schuetze, Rashmi Chugh, Robert G. Maki, Denise K. Reinke, Brigitte C. Widemann, Ae Rang Kim
Summary: This study analyzes the outcomes of patients with malignant peripheral nerve sheath tumors enrolled on phase II trials conducted by SARC and evaluates the effect of enrollment characteristics on progression-free survival. The results provide a historical baseline for future clinical trials in patients with MPNST.
Review
Oncology
Pampina Pilavaki, Myrofora Panagi, Samia Arifi, Robin L. Jones, Triantafyllos Stylianopoulos, Anastasia Constantinidou
Summary: Sarcomas are a diverse group of malignant tumors that arise from mesenchymal tissue and account for 1% of adult malignancies. Surgical excision and conventional chemotherapy are the mainstay of treatment for local and advanced disease, respectively. Immunotherapy has shown promise in multiple cancers, but its efficacy in sarcomas remains uncertain. Clinical trials and studies are ongoing to determine the role of immunotherapy in specific sarcoma subtypes.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Patrick Schoffski, Mehdi Lahmar, Anthony Lucarelli, Robert G. Maki
Summary: This article describes an ongoing clinical trial evaluating the efficacy of BI 907828 versus doxorubicin as first-line treatment for advanced DDLPS. The study shows that BI 907828 is able to inhibit the growth of DDLPS and has better efficacy compared to the chemotherapy drug doxorubicin.
Article
Oncology
Gabriella N. Tortorello, Cimarron E. Sharon, Kevin L. L. Ma, Nikhita Perry, Jacob E. Shabason, Robert G. Maki, John T. Miura, Giorgos C. Karakousis
Summary: This study analyzed the use and effectiveness of neoadjuvant chemotherapy (NCT) in high-risk soft tissue sarcoma (STS) patients receiving neoadjuvant radiation therapy (NRT). The results showed that NCT was associated with improved survival, although its usage has decreased over time.
JOURNAL OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Anne-Rose W. Schut, Leanne E. de Bruin, Belle H. de Rooij, Emma Lidington, Milea J. M. Timbergen, Winette T. A. van Der Graaf, Winan J. van Houdt, Johannes J. Bonenkamp, Robin L. Jones, Dirk. J. Gruenhagen, Stefan Sleijfer, Spyridon Gennatas, Cornelis Verhoef, Olga Husson
Summary: By studying the level of symptom burden, DTF patients can be categorized into four subgroups, with patients in the high symptom burden subgroup having poorer health-related quality of life and higher healthcare utilization. Understanding the symptom burden of DTF patients can help identify high-risk patients and tailor supportive care to individual needs.
Review
Oncology
Antonia Digklia, Ana Dolcan, Monika A. Kucharczyk, Robin L. Jones, Andrea Napolitano
Summary: Ewing sarcoma is a rare and highly malignant sarcoma that primarily affects young individuals but can occur at any age. It most commonly occurs in the long bones of the extremities and pelvis, but can also occur in soft tissues in older patients. There is currently no standard surveillance schedule for adult patients with Ewing sarcoma after initial treatment, leading to challenges in detecting recurrence and managing long-term side effects. This review aims to summarize available data on treatment-associated complications in long-term survivors and provide recommendations for optimizing follow-up and managing sequelae.
CANCER MANAGEMENT AND RESEARCH
(2023)
Article
Oncology
Nam Bui, Hilary Dietz, Sheima Farag, Angela C. Hirbe, Michael J. Wagner, Brian A. Van Tine, Kristen Ganjoo, Robin L. Jones, Vicki L. Keedy, Elizabeth J. Davis
Summary: This study retrospectively analyzed the clinical characteristics and outcomes of 74 patients with dedifferentiated chondrosarcoma (DDCS). Most patients presented with localized disease and underwent surgical resection as the main treatment. Chemotherapy was mainly used for metastatic cases, with partial responses observed in a small number of patients treated with doxorubicin with cisplatin or ifosfamide and single-agent pembrolizumab. Other regimens resulted in stable disease as the best response. Prolonged stable disease was achieved with pazopanib and immune checkpoint inhibitors. Due to the poor outcomes and limited benefit of conventional chemotherapy in DDCS, future studies should focus on the role of molecularly targeted therapies and immunotherapy.
Article
Oncology
Gabriella N. N. Tortorello, Eric H. H. Li, Cimarron E. E. Sharon, Kevin L. L. Ma, Robert G. G. Maki, John T. T. Miura, Douglas L. L. Fraker, Ronald P. P. DeMatteo, Giorgos C. C. Karakousis
Summary: This study analyzed data from 2656 patients with high-grade retroperitoneal sarcoma and found that neoadjuvant chemotherapy did not confer a survival advantage in 5-year overall survival. The authors called for more prospective randomized controlled studies to confirm this finding.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Jacob Jordan, Robert G. Maki
Summary: Weighted toxicity score provides a rapid comparison of toxicity between two arms in a clinical trial. It helps clinicians define the cost-benefit ratio of specific treatments and assess toxicity prospectively during a cancer clinical trial.
Article
Multidisciplinary Sciences
Jessica P. Burns, Christopher Wilding, Lukas Krasny, Xixuan Zhu, Madhumeeta Chadha, Yuen Bun Tam, P. S. H. Hari, Aswanth Mahalingam, Alexander T. J. Lee, Amani Arthur, Nafia Guljar, Emma Perkins, Valeriya Pankova, Andrew Jenks, Vanessa Djabatey, Cornelia Szecsei, Frank McCarthy, Chanthirika Ragulan, Martina I. Milighetti, Theodoros Roumeliotis, Stephen Crosier, Martina S. Finetti, Jyoti Choudhary, Ian Judson, Cyril F. Fisher, Eugene Schuster, Anguraj W. Sadanandam, Tom Chen, Daniel Williamson, Khin L. Thway, Robin Jones, Maggie C. U. H. Cheang, Paul Huang
Summary: This study conducted comprehensive proteomic profiling of tumor specimens from 321 STS patients and identified three proteomic subtypes within leiomyosarcomas with distinct myogenesis and immune features, anatomical site distribution and survival outcomes. The complement cascade is suggested as a candidate immunotherapeutic target for undifferentiated pleomorphic sarcomas and dedifferentiated liposarcomas. The study also defines functional signatures called Sarcoma Proteomic Modules that are independent prognostic factors for distant metastasis.
NATURE COMMUNICATIONS
(2023)
Article
Oncology
Steven Attia, Victor Villalobos, Nadia Hindi, Andrew J. Wagner, Bartosz Chmielowski, Gerard J. Oakley, Patrick M. Peterson, Matteo Ceccarelli, Robin L. Jones, Mark A. Dickson
Summary: Gemcitabine plus docetaxel is an effective treatment for soft tissue sarcomas. However, the prognosis for patients remains poor, emphasizing the need for novel therapies. The ANNOUNCE 2 trial explored the addition of olaratumab to the treatment regimen for advanced STS. The study found no significant difference in overall survival between the investigational and control arms.
Review
Oncology
Marin Golcic, Robin L. Jones, Paul Huang, Andrea Napolitano
Summary: Gastrointestinal stromal tumours (GIST) is the most common mesenchymal tumour of the gastrointestinal tract. Surgical treatment is recommended for localised GIST, while systemic treatment is the main approach for metastatic or unresectable disease. The duration of neoadjuvant treatment with imatinib is not clearly recommended, but it is usually given for 4 to 12 months. Personalized treatment options based on the molecular profile of GIST, patient characteristics, and medication adverse events are possible with the development of various systemic treatment options.